110 results about "Myocardial Ischemic Reperfusion Injury" patented technology

The invention relates to the technical field of natural medicine and particularly relates to the use of a flavonoid compound originated from Dracocephalum moldavica in protecting myocardial ischemia reperfusion injury. A pharmacology experiment proves that the effect of protecting myocardial ischemia reperfusion injury of lonicerin, kaempferol and galuteolin is better than that of other flavonoid compounds and than that of general flavone of Dracocephalum moldavica.

The invention relates to application of CREG protein, in particular to application of the CREG protein or an active fragment of the CREG protein to preparation of drugs for preventing and/or treating myocardial Ischemia-reperfusion injury. The invention further relates to application of a recombinant vector or recombinant cell expressing the CREG protein or an active fragment of the CREG protein to preparation of the drugs for preventing and/or treating the myocardial Ischemia-reperfusion injury. The invention further relates to a preparation compound which contains the CREG protein or an active fragment of the CREG protein as well as the recombinant vector or recombinant cell expressing the CREG protein or the active fragment of the CREG protein, and can inhibit down-regulated expression of the CREG protein or an active fragment of the CREG protein or promote up-regulated expression of the CREG protein or an active fragment of the CREG protein.

The invention discloses two bromophenol compounds and a pharmaceutical application of their pharmaceutically-acceptable salts, specifically an application in the preparation of a myocardial ischemia-reperfusion injury protection drug. The two compounds and their pharmaceutically-acceptable salts can protect cardiomyocytes during rat heart acute ischemia so as to make rat heart functions complete.After routine intravenous administration, SOD activity after myocardial ischemia-reperfusion is raised, myocardial compliance is improved, serum LDH, serum CK, serum cTnT and MDA level after myocardial ischemia-reperfusion is remarkably reduced, myocardial injury is minimized, and FasmRNA after myocardial ischemia-reperfusion can be remarkably inhibited and reduced so as to inhibit cardiomyocyte apoptosis after myocardial ischemia-reperfusion. Therefore, the two bromophenol compounds and their pharmaceutically-acceptable salts have a clear myocardial ischemia-reperfusion injury protection function, thus providing a new method and means for the clinical treatment of myocardial ischemia-reperfusion injury and opening up a new direction for clinical medication.

The invention provides a drug for reducing myocardial damage caused by ischemia reperfusion or a drug for treating cardiac ischemic diseases. The drug is prepared by taking a DNA tetrahedron as an active ingredient and adding pharmaceutically acceptable auxiliary materials, wherein the DNA tetrahedron is a tetrahedral structure formed by hybridization of four DNA single strands according to the same amount of substance. The drug has good protection and repair functions on myocardium, inhibits apoptosis of myocardial cells, and has the good curative effect on myocardial infarction and other ischemic diseases.

The invention discloses a traditional Chinese medicine composition for preventing and treating myocardial ischemia reperfusion injury. The traditional Chinese medicine composition is a medicament prepared by the following active pharmaceutical ingredients in portions by weight: 15-30 portions of membranous milkvetch root, 12-30 portions of motherwort herb, 6-15 portions of longstamen onion bulb, 12-30 portions of hawthorn fruit, 20-45 portions of whole trichosanthes, 9-18 portions of radix salviae miltiorrhizae, 9-18 portions of prepared pinellia tuber and 9-18 portions of kudzuvine root. In addition, the invention further relates to a preparation method for the traditional Chinese medicine composition.

This invention relates to methods of treating or preventing type 2 diabetes, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic microangiopathy, diabetic macroangiopathy, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury and/or insulin resistance syndrome (IRS) in mammals, particularly in humans, by administering a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor or a pharmaceutical composition containing such an inhibitor. This invention also relates to combinations comprising NHE-1 inhibitors and a second pharmaceutical agent, said combinations being useful in treating type 2 diabetes, IRS, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury, diabetic microangiopathy and/or diabetic macroangiopathy.

The invention discloses an application of polysaccharides of taxus mairei in the preparation of drugs for preventing and controlling the myocardial ischemia reperfusion injury. The drugs can be any pharmaceutically acceptable preparation, and the content of the polysaccharides of taxus mairei in the preparation by weight percent is not less than 60 percent; the polysaccharides of taxus mairei can improve the LV-dp/dXmaX and SOD ability after the myocardial ischemia reperfusion, improve the myocardial compliance, significantly reduce the serum LDH, the serum cTnT and the MDA level after the myocardial ischemia reperfusion and reduce the myocardial injury; the polysaccharides of taxus mairei can significantly inhibit and lower the FaS mRNA and the protein expression thereof, the MCP-1 mRNA and the protein expression thereof and the NCF-47K mRNA and the protein expression thereof after the myocardial ischemia reperfusion, thereby further inhibiting the myocardial cell apoptosis after the myocardial ischemia reperfusion. Therefore, the polysaccharides of taxus mairei have the effects of preventing and controlling the myocardial ischemia reperfusion injury and developing a new clinical application field of the polysaccharides of taxus mairei.

The invention discloses an application of GSDMD as an early diagnosis marker of myocardial ischemia-reperfusion injury, and particularly discloses a diagnostic reagent or a kit for detecting myocardial ischemia-reperfusion injury prepared from GSDMD. The GSDMD is remarkably increased after myocardial ischemia reperfusion is verified at animal and human levels, so that the myocardial ischemia reperfusion injury can be diagnosed and predicted by detecting the level of the GSDMD in peripheral blood or in-vitro myocardial tissue samples of a tested individual, and a new way is provided for early diagnosis of the myocardial ischemia reperfusion injury.

Methods, uses, kits and products are described for the prevention and treatment of ischemia-associated cardiopathies such as myocardial ischemia/reperfusion (I/R) injury, based on the selective modulation of CD36.

The invention relates to a myocardium targeted preparation containing a pterostilbene compound. Specifically, the pterostilbene compound includes pterostilbene and analogues thereof. Because of structural modification optimization, pterostilbene analogues have more prominent effect than pterostilbene in the aspect of preventing myocardial ischemia reperfusion injury. After intravenous injection, the myocardium targeted preparation can enable slow release of pterostilbene compound so as to prolong the half-life period in blood plasma, at the same time can concentrate the pterostilbene compoundat the heart part relatively, thereby increasing the concentration in myocardium, improving the effect of the pterostilbene compound on myocardial ischemia reperfusion injury, especially diabetic myocardial ischemia reperfusion injury, also the drug dosage can be reduced, and the drug concentration of other tissue parts in the whole body can be reduced relatively, therefore the toxic and side effects are reduced.

The invention discloses a method for constructing an ordered ischemic-cardiomyocyte-mitochondria-targeting drug-loading (model drugs such as puerarin, baicalin, and the like respectively can act on ischemic cardiomyocyte mitochondria so as to treat myocardial ischemia reperfusion injury ) nanometer micelle, wherein the method comprises synthesizing a TPP-PEG-PE block copolymer, and preparing an ordered targeting drug-loaded nanometer micelle. According to the present invention, the puerarin drug is precisely delivered to ischemic cardiomyocyte mitochondria by using the ordered targeting drug-loaded nanometer micelle so as to provide the pharmacological effect, wherein the drug carrier is accumulated in the ischemic myocardium at the early stage of the infarct in a targeting manner throughthe EPR effect of the PEG-PE nanometer micelle, and the charge effect of the TPP cation mediates the drug carrier to enter the negatively charged cardiomyocyte mitochondria to deliver the puerarin andother drugs to the ischemic cardiomyocyte mitochondria in stages so as to achieve the precise administration.

The invention discloses a screening method of tsRNA related to myocardial ischemia reperfusion. The method is characterized by comprising the following steps of building a rat myocardial ischemia reperfusion model, and screening out differentially expressed tsRNA in a myocardial ischemia reperfusion process by adopting a sequencing method; and building an in-vivo rat myocardial ischemia reperfusion model and an in-vitro myocardial cell hypoxia reoxygenation model, and adopting real-time quantitative PCR for sequencing verification. According to the scheme, the tsRNA participates in the myocardial ischemia reperfusion injury process, and an application of the tsRNA in the aspect of myocardial ischemia reperfusion injury treatment is provided, so that a new idea is provided for people to research a pathophysiology process of myocardial ischemia reperfusion injury, and a new molecular basis or a treatment target is provided for prevention and treatment of myocardial ischemia reperfusion injury.

The invention relates to the technical field of medicines, in particular to application of an alpha-carboline derivative in preparation of an anoxia-reoxygenation injury drug against a myocardial ischemia-reperfusion injury. The compound is stable in solution, has an obvious protective activity against a myocardial anoxia-reoxygenation injury, especially an anoxia-reoxygenation injury of a myocardial ischemia-reperfusion injury, and can protect myocardium from an anoxia-reoxygenation injury at 100 mu mol/L, and thus a new option is provided for protection of the anoxia-reoxygenation injury against a myocardial ischemia-reperfusion injury and the myocardial anoxia-reoxygenation injury.

The invention discloses a cyclosporine A drug delivery system for treating myocardial ischemia reperfusion injury. The cyclosporine A drug delivery system for treating myocardial ischemia reperfusion injury is characterized in that the drug delivery system is high drug-loading polymeric micelles double-responded by matrix metalloproteinase and active oxygen and is obtained by self-assembling of block copolymer polyethylene glycol-matrix metalloproteinase substrate peptide-polyaspartic acid-phenylboronic acid, the block copolymer wraps cyclosporine A to conduct self-assembling through cooperation action, so that drug carrying micelles are obtained. The drug delivery system can act on ischemic myocardial tissue through passive targeting action to release the cyclosporine A quickly under action of the matrix metalloproteinase and the active oxygen and exert the protecting function for myocardial ischemia reperfusion injury, and new strategies for preventing and treating myocardial ischemia reperfusion injury are provided.

The invention discloses a triterpenoid saponin compound. The triterpenoid saponin compound is extracted from clematis tangutica and then is subjected to separation and purification. The triterpenoid saponin compound is shown in the formula (I) and comprises an aglycone of 3 beta, 23-dihydroxyolean-18-olefine acid. The triterpenoid saponin compound has obvious effects of protecting anoxic/oxygen-rich model-induced myocardial cell injuries, can be used for preparation of a drug for treating ischemic heart diseases, is a lead compound for researching and preparing a novel drug for treating ischemic heart diseases, and can provide a clinical drug which is used for treating myocardial ischemia/reperfusion injuries and has strong activity and small toxic and side effects.

The invention provides an application of sweet almond oil in preparing a medicament for treating myocardial ischemia reperfusion injury. The medicament for preventing and treating myocardial ischemia reperfusion injury is prepared from sweet almond oil as an active component and is used in the form of soft capsules which are prepared directly from sweet almond oil by a conventional preparation method of soft capsules. Shown by drug effect tests, the sweet almond oil is capable of improving the hypoxia tolerance of the myocardial tissues of rats, enhancing the tolerance of the myocardial tissues to ischemia reperfusion myocardial injury, improving the antioxidant ability of the myocardial tissues of rats with ischemia reperfusion, and reducing the extent of injury to the myocardial tissuesof rats caused by ischemia reperfusion. The almond oil is a natural edible material with unsaturated fatty acid as a main active component, and can not generate toxic side effect on the body when taken in a certain dose range for a long term.

The invention relates to application of a traditional Chinese medicine composition in preparation of a medicine for preventing and/or treating myocardial ischemia reperfusion injury. The traditional Chinese medicine composition is prepared from radix rehmanniae praeparata, rhizoma coptidis, radix paeoniae alba, radix scutellariae, colla corii asini and poria. The traditional Chinese medicine composition can obviously control the weight gain of a rat after ovariectomy and can obviously reduce the infarction area of the rat under myocardial ischemia-reperfusion injury after ovariectomy; the levels of serum LDH and serum CK after myocardial ischemia reperfusion are remarkably reduced, and myocardial damage is reduced; and according to the application, the expression of GRP78 protein, CHOP protein, Active-caspase12 protein and the Active-caspase3 protein after the myocardial ischemia reperfusion can be significantly inhibited and reduced, so as to inhibit the apoptosis of the myocardial cells after the myocardial ischemia reperfusion.

The invention relates to the field of biological medicine, in particular to application of herba houttuyniae extracts to preparation of a medicine preparation for preventing and treating related diseases of myocardial ischemia reperfusion injury. The herba houttuyniae is herb of houttuynia cordata Thunb., and is prepared into a soft capsule through the processes of freezing, pulverization, soaking, filtration, concentration and the like or is prepared into a preparation for clinical application according to a pharmacy process. The herba houttuyniae extract preparation can obviously reduce the myocardial infarction area of a myocardial ischemia reperfusion injury rat; and the result shows that the herba houttuyniae extract preparation has the obvious prevention and treatment effects on the related diseases of the myocardial ischemia reperfusion injury, and can be used as functional food or medicine for preventing and treating the related diseases of the myocardial ischemia reperfusion injury of the human body.

The invention discloses o-nitro caffeic acid phenethyl ester with a structural formula shown as formula I. The method includes: subjecting caffeic acid and thionyl chloride to acylation reaction to generate caffeoyl chloride, then in the presence of a catalyst, subjecting the caffeoyl chloride and o-nitrophenylethanol to esterification reaction in an organic solvent, thus obtaining o-nitro caffeic acid phenethyl ester. Compared with caffeic acid phenethyl ester, the o-nitro caffeic acid phenethyl ester has better effect of protecting antioxidant enzyme activity, stronger ability of clearing oxygen free radicals, and better effects of maintaining antioxidant ability of myocardial cells, protecting normal cell structure and alleviating cell oxidative damage, can significantly reduce ischemia/reperfusion myocardial cell apoptosis, decreases myocardial infarction area, can be used for preparation of drugs for improving ischemia reperfusion injury, and plays an important role in treatment of cardiovascular system diseases. (formula I).

The invention discloses application of irisin in the preparation of drugs for preventing myocardial ischemia reperfusion injuries. Experimental results show that irisin can decrease the myocardial infarction area caused by ischemia reperfusion, reduce the increase of the contents of lactate dehydrogenase (LDH), troponin (cTnI), creatine kinase (CK), and other myocardial enzyme markers caused by ischemia reperfusion, meanwhile reducing the inflammatory response, myocardial apoptosis, and oxidative stress response caused by myocardial ischemia reperfusion, promote peroxysome proliferator-activated receptor γ nuclear translocation, and inhibit nuclear transcription factor NF-κB nuclear translocation and accordingly decrease myocardial structure injuries and load increase caused by ischemia reperfusion. Therefore, irisin can be used for preventing and decreasing myocardial reperfusion injuries and has important clinical significance on the treatment of myocardial ischemia.

The invention discloses an application of hydroxysafflor yellow B in prevention and treatment of myocardial ischemia reperfusion injury. The experiment result prompts that the hydroxysafflor yellow Bhas prevention and protection effects for an in-vitro ischemia reperfusion injury model, the effect has a dose-dependent relationship, and is related with anti-inflammation, antioxidation and anti-apoptosis effects of the hydroxysafflor yellow B.